Furthermore, a FAP-activated prodrug derived from thapsigargin (a highly toxic natural plant product that stimulates increased intracellular calcium levels to cause apoptosis) is also reported to decrease tumor burden in LNCaP prostate cancer xenografts [309]. This evidence concerns the gene FAP and Familial prostate cancer.